Rocket Pharmaceuticals
RCKT
180 hedge funds and large institutions have $341M invested in Rocket Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 71 increasing their positions, 66 reducing their positions, and 33 closing their positions.
2,246% more call options, than puts
Call options by funds: $2.37M | Put options by funds: $101K
2.21% more ownership
Funds ownership: 89.07% → 91.28% (+2.2%)
8% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 66
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $348M → $341M (-$6.99M)
10% less funds holding
Funds holding: 199 → 180 (-19)
45% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.95M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$5.18M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.26M |
| 4 |
JP Morgan Chase
New York
|
+$3.96M |
| 5 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
+$3.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
-$9.74M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.86M |
| 3 |
D.E. Shaw & Co
New York
|
-$4.05M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.65M |
| 5 |
Morgan Stanley
New York
|
-$3.18M |
RCKT Hedge Fund Activity: Q2 2026 in Review
180 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q2 2026, worth a combined $341M — down 2% from $348M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of RCKT and 18 opened new positions — a net loss of 15 holders — while 66 trimmed existing stakes and 71 added.
The largest buyer was BlackRock, adding an estimated $6.95M. The largest seller was Nuveen, cutting an estimated $9.74M.
- 180 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q2 2026, down from 199 in Q1 2026.
- Funds reported $341M of Rocket Pharmaceuticals stock for Q2 2026, down 2% quarter-over-quarter.
- 18 funds opened new Rocket Pharmaceuticals positions in Q2 2026 and 33 closed out, a net change of -15 holders.
- The largest Rocket Pharmaceuticals buyer in Q2 2026 was BlackRock, an estimated $6.95M added.
- The largest Rocket Pharmaceuticals seller in Q2 2026 was Nuveen, an estimated $9.74M sold.
Based on aggregated 13F filings for Q2 2026.